Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BYF1

UPID:
ACE2_HUMAN

ALTERNATIVE NAMES:
Angiotensin-converting enzyme homolog; Angiotensin-converting enzyme-related carboxypeptidase; Metalloprotease MPROT15

ALTERNATIVE UPACC:
Q9BYF1; A0A7D6JAD5; C7ECU1; Q6UWP0; Q86WT0; Q9NRA7; Q9UFZ6

BACKGROUND:
The Angiotensin-converting enzyme 2, with alternative names such as Angiotensin-converting enzyme homolog, is a crucial regulator in the cardiovascular system. It modulates blood volume and systemic vascular resistance through its action on angiotensin peptides, promoting cardiovascular homeostasis. ACE2 also exhibits high efficiency in cleaving other significant peptides and serves as a receptor for various human coronaviruses, highlighting its multifunctional role.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Angiotensin-converting enzyme 2 offers a promising avenue for developing novel therapeutic interventions for cardiovascular disorders and viral diseases, including COVID-19.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.